Proteome Alterations Associated With the V144D SPTLC1 Mutation That Causes Hereditary Sensory Neuropathy-I

Scott E. Stimpson¹, 3, 4, Jens R. Coorssen², 3, 4, 5,*, Simon J. Myers¹, 3, 4, 5,*

¹ Neuro-Cell Biology Laboratory, Western Sydney University, Australia; ² Molecular Physiology, Western Sydney University, Australia; ³ Molecular Medicine Research Group, Western Sydney University, Australia; ⁴ School of Science and Health, Western Sydney University, Australia; ⁵ School of Medicine, Western Sydney University, Australia.

*Corresponding author. Tel: 61 02 4620 3383, 61 4620 3802; E-mail: s.myers@uws.edu.au; j.coorssen@uws.edu.au

Citation: Stimpson SE, Coorssen JR, Myers SJ, Proteome Alterations Associated With the V144D SPTLC1 Mutation That Causes Hereditary Sensory Neuropathy-I. Electronic J Biol, 11:4

Received: November 16, 2015; Accepted: December 11, 2015; Published: December 17, 2015

Abstract

Background: Hereditary sensory neuropathy type I is the most common subtype and presents with clinical onset in the second to third decade of life with progressive degeneration of the dorsal root ganglion neurons. Three different missense mutations in the gene encoding for serine palmitoyltransferase long chain subunit 1 have been linked to HSN-I. Here we quantitatively assess the proteomes and identify marked protein alterations in both mitochondria and endoplasmic reticulum from HSN-I patient lymphoblasts which harbour the V144D mutation.

Methods: Mitochondria and endoplasmic reticulum were fractionated and lysed from control and patient-derived lymphoblasts. Protein samples were separated into total soluble and total membrane fractions and analysed using a well-established top-down proteomic protocol. Altered protein species were identified by LC MS/MS.

Results: Using a detailed proteomic approach, we identified 36 proteins that were completely altered in abundance in cells harbouring the V144D SPTLC1 mutation relative to normal controls.

Conclusion: The data establish that major protein alterations occur in both the endoplasmic reticulum, where the SPTLC1 protein resides, and in the mitochondria from V144D patient lymphoblasts. These proteins potentially play a major role in disease pathogenesis and may thus help to further elucidate the molecular mechanism(s) underlying hereditary sensory neuropathy type I and might also prove to be potential therapeutic targets.

Keywords: Mitochondria; Endoplasmic reticulum; SPTLC1; HSN-I; Proteomics.

Research Article

1. Introduction

Hereditary sensory neuropathy type I (HSN-I) is the most common subtype of the HSNs [1], characterised by the progressive degeneration of the dorsal root ganglion (DRG). Onset of clinical symptoms is between the second and third decade of life [2]. Heterozygous mutations in the serine palmitoyltransferase (SPT) long chain subunit 1 (SPTLC1) have been identified as the cause of HSN-I [3,4]. The associated mutations in this gene occur at single amino acids which are highly conserved throughout different species and are therefore likely to interfere with SPT functionality and structure [5].

SPT is a pyridoxal 5’- phosphate dependent multimeric enzyme that catalyses the first step in the biosynthesis of sphingolipids, ceramide and sphingomyelin [6]. Mutations in the SPT subunits thus result in potential dysfunction and perturbations in sphingolipid synthesis and metabolism linked to a variety of diseases, in particular HSN-I [7]. As the rate determining enzyme in the de novo sphingolipid synthesis pathway, SPT is therefore a key enzyme in the regulation of cellular sphingolipid content by condensation of palmitoyl coenzyme A (CoA) with L-serine to form 3-ketodihydrosphingosine [8-10].

We recently noted altered protein expression in the mitochondria and ER from HSN-I (SPTLC1 V144D) mutant lymphoblasts [11,12]. In order to improve characterisation, a more detailed (i.e. ‘deeper’) top down analysis of the total membrane and total soluble proteomes from the mitochondria and ER of control and HSN-I (SPTLC1 V144D) patient lymphoblasts was carried out.

Numerous protein species were found to change markedly in abundance in the mitochondria and ER from the HSN-I (SPTLC1 V144D) patient
lymphoblasts; these proteins are involved in energy metabolism, catalytic activity, protein transport, oxidative stress and the cytoskeleton. These protein alterations reflect the changing cellular events that underlie HSN-I.

2. Results
2.1 Gel images of mitochondrial and ER membrane and soluble proteins from control and patient derived lymphoblasts

All membrane and soluble protein samples were well-resolved proteomes covering the entire MW and pI range of the gels. The total numbers of resolved protein species for mitochondrial and ER membrane soluble samples are summarised in Table 1.

Table 1. Total protein species resolved by 2D from mitochondrial and ER membrane and soluble fractions obtained from controls and HSN-I (SPTLC1 V144D) patient lymphoblast.

<table>
<thead>
<tr>
<th>Organelle</th>
<th>Membrane</th>
<th>Soluble</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>V144D</td>
</tr>
<tr>
<td>Mitochondrial</td>
<td>550 ± 9</td>
<td>561 ± 9</td>
</tr>
<tr>
<td>Endoplasmic Reticulum</td>
<td>558 ± 6</td>
<td>577 ± 5</td>
</tr>
</tbody>
</table>

2.2 Functions of the identified proteins in mitochondrial and ER fractions

Proteins identified from mitochondrial and ER fractions were classified into four main types: energy metabolism, catalytic activity, protein transport, and oxidative stress. Analysis of the membrane and soluble mitochondrial and ER protein profiles from control and HSN-I (SPTLC1 V144D) patient lymphoblasts revealed protein species alterations, change in abundance greater than or equal to 2.0 fold, in the V144D cells relative to control lymphoblasts. The analysis revealed 36 protein species that were located at varying pI / MW (kDa) coordinates. These proteins were excised; digested and LC/MS/MS analysis was carried out to identify these proteins (protein identifications are summarized in Tables 2-5).

Table 2. Summary table of mascot protein identification. LC-MS/MS and Mascot Database searching identified a number of proteins from control and V144D lymphoblasts isolated mitochondrial membrane proteins.

<table>
<thead>
<tr>
<th>Spot Number</th>
<th>Protein Identified</th>
<th>Accession Number</th>
<th>Unique peptides matched</th>
<th>Sequence Coverage</th>
<th>Mascot Protein Score</th>
<th>Predicted pI</th>
<th>Predicted Mw (kDa)</th>
<th>Mascot pI</th>
<th>Mascot Mw (kDa)</th>
<th>Fold Change in V144D</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Succinate Dehydrogenase Flavoprotein Subunit, Mitochondrial</td>
<td>P31040</td>
<td>23</td>
<td>24%</td>
<td>617</td>
<td>6.5</td>
<td>70</td>
<td>7.06</td>
<td>73.7</td>
<td>6.1 Fold ↑</td>
</tr>
<tr>
<td>2</td>
<td>Aldehyde Dehydrogenase X, Mitochondrial</td>
<td>P30837</td>
<td>20</td>
<td>26%</td>
<td>340</td>
<td>6.1</td>
<td>50</td>
<td>6.36</td>
<td>57.6</td>
<td>2.2 Fold ↑</td>
</tr>
<tr>
<td>3</td>
<td>Calcium Binding Mitochondrial Carrier Protein SCaMc-1</td>
<td>Q6NUK1</td>
<td>19</td>
<td>22%</td>
<td>98</td>
<td>5.7</td>
<td>45</td>
<td>6.22</td>
<td>53.5</td>
<td>2.6 Fold ↓</td>
</tr>
<tr>
<td>4</td>
<td>Pyruvate Dehydrogenase E1 Component Subunit Alpha, Somatic Form, Mitochondrial</td>
<td>P31930</td>
<td>28</td>
<td>38%</td>
<td>971</td>
<td>5.5</td>
<td>50</td>
<td>5.94</td>
<td>53.3</td>
<td>4.0 Fold ↑</td>
</tr>
<tr>
<td>5</td>
<td>Voltage-Dependent Anion-Selective Channel Protein 1</td>
<td>P08559</td>
<td>7</td>
<td>13%</td>
<td>23</td>
<td>7.9</td>
<td>38</td>
<td>8.17</td>
<td>44</td>
<td>3.2 Fold ↑</td>
</tr>
<tr>
<td>6</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>18</td>
<td>70%</td>
<td>802</td>
<td>8.3</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Absent in V144D</td>
</tr>
<tr>
<td>7</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>15</td>
<td>63%</td>
<td>704</td>
<td>6.6</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Only present in V144D</td>
</tr>
</tbody>
</table>

Table 2 (continued)
Table 3. Summary table of mascot protein identification. LC-MS/MS and Mascot Database searching identified a number of proteins from control and V144D lymphoblasts isolated mitochondrial soluble proteins.

<table>
<thead>
<tr>
<th>Spot Number</th>
<th>Protein Identified</th>
<th>Accession Number</th>
<th>Unique peptides matched</th>
<th>Sequence Coverage</th>
<th>Mascot Protein Score</th>
<th>Predicted pl</th>
<th>Predicted Mw (kDa)</th>
<th>Mascot pI</th>
<th>Mascot Mw (kDa)</th>
<th>Fold Change in V144D</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ezrin</td>
<td>P15311</td>
<td>55</td>
<td>55%</td>
<td>1021</td>
<td>5.5</td>
<td>67</td>
<td>5.94</td>
<td>69.5</td>
<td>3.9 Fold ↓</td>
</tr>
<tr>
<td>2</td>
<td>Prolyl 4-hydroxylase subunit Alpha 1</td>
<td>P13674</td>
<td>40</td>
<td>58%</td>
<td>1188</td>
<td>5.4</td>
<td>60</td>
<td>5.70</td>
<td>61.3</td>
<td>3.0 Fold ↑</td>
</tr>
<tr>
<td>3</td>
<td>60 kDa heat shock protein, Mitochondrial</td>
<td>P10809</td>
<td>26</td>
<td>31%</td>
<td>694</td>
<td>5.2</td>
<td>58</td>
<td>5.70</td>
<td>61.2</td>
<td>2.7 Fold ↑</td>
</tr>
<tr>
<td>4</td>
<td>Dipeptidyl Peptidase 1</td>
<td>Q9Y2B0</td>
<td>14</td>
<td>16%</td>
<td>534</td>
<td>7.9</td>
<td>43</td>
<td>8.35</td>
<td>44</td>
<td>2.6 Fold ↑</td>
</tr>
<tr>
<td>5</td>
<td>Pyruvate dehydrogenase E1 component subunit alpha, somatic form, Mitochondrial</td>
<td>P08559</td>
<td>26</td>
<td>38%</td>
<td>634</td>
<td>6.4</td>
<td>49</td>
<td>6.54</td>
<td>52.6</td>
<td>2.5 Fold ↑</td>
</tr>
<tr>
<td>6</td>
<td>Inorganic Pyrophosphatase 2, Mitochondrial</td>
<td>Q9H2U2</td>
<td>36</td>
<td>59%</td>
<td>1265</td>
<td>7.0</td>
<td>32</td>
<td>7.07</td>
<td>38.4</td>
<td>2.2 Fold ↑</td>
</tr>
<tr>
<td>7</td>
<td>Pro-Cathepsin H</td>
<td>P09668</td>
<td>21</td>
<td>48%</td>
<td>581</td>
<td>6.1</td>
<td>30</td>
<td>8.35</td>
<td>38</td>
<td>2.2 Fold ↑</td>
</tr>
<tr>
<td>8</td>
<td>Peroxisome proliferator-activated receptor-alpha, Mitochondrial</td>
<td>Q13162</td>
<td>36</td>
<td>69%</td>
<td>1350</td>
<td>5.6</td>
<td>25</td>
<td>5.86</td>
<td>30.7</td>
<td>2.1 Fold ↑</td>
</tr>
<tr>
<td>9</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>31</td>
<td>88%</td>
<td>1354</td>
<td>8.3</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Absent from V144D</td>
</tr>
<tr>
<td>10</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>27</td>
<td>76%</td>
<td>998</td>
<td>6.6</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Only present in V144D</td>
</tr>
</tbody>
</table>

Table 4. Summary table of mascot protein identification. LC-MS/MS and Mascot Database searching identified a number of proteins from control and V144D lymphoblasts isolated ER membrane proteins.

<table>
<thead>
<tr>
<th>Spot Number</th>
<th>Protein Identified</th>
<th>Accession Number</th>
<th>Unique peptides matched</th>
<th>Sequence Coverage</th>
<th>Mascot Protein Score</th>
<th>Predicted pl</th>
<th>Predicted Mw (kDa)</th>
<th>Mascot pI</th>
<th>Mascot Mw (kDa)</th>
<th>Fold Change in V144D</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Heterogeneous nuclear ribonucleoprotein D-like</td>
<td>O14979</td>
<td>8</td>
<td>14%</td>
<td>230</td>
<td>8.1</td>
<td>40</td>
<td>9.59</td>
<td>46.6</td>
<td>3.5 Fold ↓</td>
</tr>
<tr>
<td>2</td>
<td>Serine/Threonine-protein Phosphatase PP1-Beta Catalytic Subunit</td>
<td>P62140</td>
<td>11</td>
<td>40%</td>
<td>418</td>
<td>5.2</td>
<td>35</td>
<td>5.84</td>
<td>38</td>
<td>2.0 Fold ↑</td>
</tr>
<tr>
<td>3</td>
<td>Apolipoprotein L2</td>
<td>Q9BQE5</td>
<td>11</td>
<td>42%</td>
<td>210</td>
<td>5.7</td>
<td>36</td>
<td>6.28</td>
<td>37.1</td>
<td>2.8 Fold ↓</td>
</tr>
<tr>
<td>4</td>
<td>UPF0568 Protein Cl4orf166</td>
<td>Q9Y224</td>
<td>18</td>
<td>56%</td>
<td>315</td>
<td>6.1</td>
<td>25</td>
<td>6.19</td>
<td>28.2</td>
<td>3.3 Fold ↓</td>
</tr>
<tr>
<td>5</td>
<td>Elongation Factor 1-Beta</td>
<td>P24534</td>
<td>9</td>
<td>46%</td>
<td>243</td>
<td>4.1</td>
<td>24</td>
<td>4.50</td>
<td>25</td>
<td>4 Fold ↓</td>
</tr>
<tr>
<td>6</td>
<td>Serine/Arginine-rich Splicing Factor 3</td>
<td>P94103</td>
<td>6</td>
<td>36%</td>
<td>152</td>
<td>5.8</td>
<td>17</td>
<td>9.64</td>
<td>19.5</td>
<td>2.9 Fold ↓</td>
</tr>
<tr>
<td>7</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>26</td>
<td>80%</td>
<td>1303</td>
<td>6.6</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Only present in V144D</td>
</tr>
<tr>
<td>8</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>22</td>
<td>80%</td>
<td>1065</td>
<td>8.8</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Absent from V144D</td>
</tr>
</tbody>
</table>

membrane and soluble fractions were grouped based upon their biological functionality; a pie graph has been used to provide a visual analysis of protein changes in the HSN-I (SPTLC1 V144D) disease state.
(Figure 1). This analysis indicates that the majority of the protein alterations in mitochondria are involved in catalytic activity, cytoskeleton, transport, oxidative stress, calcium binding and energy metabolism. However, whilst there is some overlap in terms of alterations to mitochondrial and ER proteins (Figure 2), many of those identified from the ER function in the areas of protein biosynthesis, apoptosis, cell proliferation, protein binding and lipid binding (Figure 1).

3. Discussion

SPT is the key rate determining enzyme in sphingolipid metabolism. Mutations within the SPTLC1 subunit thus result in potential perturbations in sphingolipid synthesis and metabolism that may be the underlying causative effects of HSN-I [7]. In initial studies, we showed that a number of mitochondrial and ER proteins are altered in abundance, correlating with the SPT mutations in patient derived cells [11-13]. Here we have carried out a more detailed top-down proteomic analysis and identified 36 protein species that change in abundance in the mitochondria and ER of HSN-I patient cells.

To identify potentially critical protein changes, mitochondria and ER were first isolated from control and HSN-I (SPTLC1 V144D) patient lymphoblasts and further separated into total membrane and total soluble protein fractions prior to high resolution top-down proteomic analyses using 2DE [14-16]. These analyses revealed numerous protein changes in both the membrane and soluble protein fractions from the control and HSN-I (SPTLC1 V144D) patient lymphoblasts. Mitochondrial protein species that changed in abundance were involved in catalytic activity, cytoskeleton, protein transport, oxidative stress, calcium binding and energy metabolism (Figure 1). The proteins identified in the ER fractions were involved in catalytic activity, cytoskeleton and lipid binding (Figure 1). While there were a number of non-related protein species that changed in the mitochondria compared to the ER, there were a number of similarities in biological processes, most notably catalytic activity, cytoskeleton, protein transport and oxidative stress [17-19] (Figure 2).

Mitochondria are known to play a role in neurodegeneration, and structural alterations have been characterised in V144D patient lymphoblasts [20], with further studies identifying changes at the protein level within isolated mitochondria [11]. The higher resolution analyses here provide more detailed information still. Oxidative stress can have an impact upon the cell, causing severe and

<table>
<thead>
<tr>
<th>Spot Number</th>
<th>Protein Identified</th>
<th>Accession Number</th>
<th>Unique peptides matched</th>
<th>Sequence Coverage</th>
<th>Mascot Protein Score</th>
<th>Predicted pl</th>
<th>Predicted Mw (kDa)</th>
<th>Mascot pl</th>
<th>Mascot Mw (kDa)</th>
<th>Fold Change in V144D</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Peroxiredoxin-2</td>
<td>P32119</td>
<td>19</td>
<td>65%</td>
<td>453</td>
<td>5.0</td>
<td>20</td>
<td>5.66</td>
<td>45.3</td>
<td>2.4 Fold ↑</td>
</tr>
<tr>
<td>2</td>
<td>Lymphocyte-Specific Protein 1</td>
<td>P33241</td>
<td>24</td>
<td>49%</td>
<td>901</td>
<td>3.5</td>
<td>50</td>
<td>4.69</td>
<td>37.4</td>
<td>3.2 Fold ↑</td>
</tr>
<tr>
<td>3</td>
<td>Proteasome Activator Complex Subunit 1</td>
<td>Q06323</td>
<td>10</td>
<td>37%</td>
<td>357</td>
<td>6.0</td>
<td>35</td>
<td>5.78</td>
<td>28.9</td>
<td>4.2 Fold ↑</td>
</tr>
<tr>
<td>4</td>
<td>Proteasome Subunit Alpha Type-3</td>
<td>P25788</td>
<td>18</td>
<td>41%</td>
<td>372</td>
<td>5.2</td>
<td>30</td>
<td>5.19</td>
<td>28.6</td>
<td>2.6 Fold ↑</td>
</tr>
<tr>
<td>5</td>
<td>Protein CDV3 Homolog</td>
<td>Q9UKY7</td>
<td>14</td>
<td>64%</td>
<td>578</td>
<td>6.2</td>
<td>60</td>
<td>6.06</td>
<td>27.3</td>
<td>2.3 Fold ↓</td>
</tr>
<tr>
<td>6</td>
<td>Chloride intracellular channel protein 1</td>
<td>O00299</td>
<td>38</td>
<td>68%</td>
<td>1174</td>
<td>5.2</td>
<td>30</td>
<td>5.09</td>
<td>27.2</td>
<td>2.7 Fold ↑</td>
</tr>
<tr>
<td>7</td>
<td>Adenine Phosphoribosyltransferase</td>
<td>P07741</td>
<td>24</td>
<td>72%</td>
<td>876</td>
<td>5.1</td>
<td>17</td>
<td>5.78</td>
<td>19.8</td>
<td>3.0 Fold ↓</td>
</tr>
<tr>
<td>8</td>
<td>Eukaryotic Translation Initiation Factor 5A-1</td>
<td>P63241</td>
<td>26</td>
<td>70%</td>
<td>898</td>
<td>4.3</td>
<td>15</td>
<td>5.08</td>
<td>17</td>
<td>2.1 Fold ↑</td>
</tr>
<tr>
<td>9</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>21</td>
<td>80%</td>
<td>1278</td>
<td>6.6</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Only present in V144D</td>
</tr>
<tr>
<td>10</td>
<td>Ig Kappa Chain C</td>
<td>P01834</td>
<td>29</td>
<td>86%</td>
<td>1609</td>
<td>8.3</td>
<td>22</td>
<td>5.58</td>
<td>12</td>
<td>Absent in V144D</td>
</tr>
</tbody>
</table>

Table 5. Summary table of mascot protein identification. LC-MS/MS and Mascot Database searching identified a number of proteins from control and V144D lymphoblasts isolated ER soluble proteins.
Figure 1. Pie graph of the identified proteins function in mitochondrial and ER fractions. Representative pie graph of proteins identified in both membrane and soluble mitochondrial and ER fractions grouped into their biological functions.

Figure 2. Similarities in protein changes identified in Mitochondria and ER. Representative graph revealing four common protein changes occurring in the mitochondria and the ER.
Figure 3. Representative 2D gels images of mitochondrial membrane and soluble proteomes from control and patient derived lymphoblasts. (A) Gel of control mitochondrial membrane proteins. (B) Gel of V144D mitochondrial membrane proteins. (C) Gel of control mitochondrial soluble proteins. (D) Gel of V144D mitochondrial soluble proteins. Red circles represent identified protein species. The molecular weights are in kilodaltons (kDa) and the IEF dimension is in pH units.

Figure 4. Representative 2D gels images of ER membrane and soluble proteomes from control and patient derived lymphoblasts. (A) Gel of control ER membrane proteins (B) Gel of V144D ER membrane proteins. (C) Gel of control ER soluble proteins. (D) Gel of V144D ER soluble proteins. Red circles represent identified protein species. The molecular weights are in kilodaltons (kDa) and the IEF dimension is in pH units.
extensive damage including protein aggregation and impaired ion transport [21]. Previously, ubiquinol cytochrome C subunit 1 was found to increase in abundance in V144D patient lymphoblasts [11]; here this protein was found to increase in abundance (i.e. 4-fold), and this was accompanied by a 2.1-fold increase in the abundance of Peroxiredoxin-4, a protein with antioxidant functions, that reduces the build-up of hydrogen peroxide via a thiol-dependent cycle [21]. These findings correlate with a potential increase in reactive oxygen species (ROS) within the disease cells, which could lead to further disruption to mitochondria.

Perturbations to energy production within neurons, having high metabolic demands, can have catastrophic consequences. Succinate dehydrogenase flavoprotein and pyruvate dehydrogenase E1 subunit are both part of the electron transport chain, and both are increased in abundance (i.e. 6.1 and 3.2 fold, respectively), likely highlighting an energy metabolism issue within the mitochondria [22]. In addition to a potential need to increase energy output, increased levels of succinate dehydrogenase could also potentially increase superoxide formation [22]. Whether these proteins apparently increased abundance is due to a direct need for increased energy or a compensatory effect due to an increase in ROS production and oxidative stress disrupting the electron transport chain's ability to produce energy remains unclear, but a destructive spiral would seem a distinct possibility.

Ca\(^{2+}\) is also required for energy production within mitochondria, but increased Ca\(^{2+}\) levels can lead to free radical generation [23]. The data identifies a 2.6-fold decrease in the Ca\(^{2+}\) binding mitochondrial carrier protein (ScaMc-1). This decrease might be a protective mechanism due to the already high levels of ROS but will also cause a decrease in ATP production within the mitochondria. Voltage dependent anion selective channel protein 1 (VDAC) allows mitochondrial influx/efflux of metabolites such as ATP, and may also have a role in regulating Ca\(^{2+}\) in mitochondria [24]. A decrease in VDAC in the V144D mutant, in conjunction with the reduction of ScaMc-1 could result in an overall decrease in intracellular Ca\(^{2+}\) levels in mitochondria and thus decreased ATP production, again strengthening the possibility for a destructive circle of cellular events.

Dipeptidyl peptidase 1, also known as Cathepsin C and Pro-cathepsin H has been shown to be pro-apoptotic by cleaving Bid and Bcl-2 family proteins released by mitochondria; greatly increasing the cascade of caspase apoptotic factors to be released [25,26]. The abundance of these proteins are increased in the mutant cells indicating a link to increased mitochondrial apoptotic process occurring (2.6 and 2.2 fold increase respectively).

Eukaryotic translation initiation factor 5A-1 (eIF5A) has been shown to regulate the Bcl-2 binding protein P53 and the P53 apoptosis pathway. In addition, eIF5A has a regulatory function in protein synthesis. Its increase in abundance of 2.1 fold in the V144D mutant may possibly be the cells response to stabilise uncontrolled protein misfolding due to ER stress [27]. Peroxiredoxin-2 was detected in the ER with an increase in abundance of 2.4 fold, peroxiredoxin-2 just like peroxiredoxin-4 found in the mitochondrial fraction is an antioxidant [28], potentially increased in the mutant state in response to increased ROS production occurring within the ER and throughout the cell.

ER stress may decrease mRNA to reduce the protein load upon the ER to help reduce the amount of misfolded proteins being produced [29], thus we see reduced levels of the serine/threonine phosphatase PP-1, serine/arginine-rich splicing factor and Elongation factor 1-beta within HSN-I (SPTLC1 V144D) patient lymphoblasts. With known ER stress occurring [20] the reduction in abundance of these proteins could be as a result of a compensatory effect reducing the load of protein synthesis occurring in the stressed ER.

Lymphocyte specific protein 1 is an F-actin binding protein [30], it's 3.2 fold increase in abundance, correlates with other cytoskeletal changes observed in the HSN-I (SPTLC1 V144D) patient lymphoblasts suggesting that maintenance of the cytoskeleton is being increased potentially due to increasing amount of ROS, known to cause actin remodelling and potential axonal retraction in the neuron [31].

Proteasome activator complex 1 (PSME1) and proteasome subunit alpha type 3 (PSMA3), degrade misfolded proteins, in an ubiquitin dependent process [32,33]. Both these proteins are increased in abundance, 4.2 and 2.6 fold respectively in the V144D patient derived lymphoblasts. Previous studies have identified Ubiquitin-40s Ribosomal Protein S27a [12], as such we see here the increase in proteasomes correlating a potential increase in the number misfolded proteins directly due to ER stress, oxidative stress or by another mechanism that affects protein conformation.

Bcl-2 family proteins are regulators of mitochondrial derived apoptosis. Bcl-2 proteins can illicit or inhibit cell death. Apolipoprotein L2 (ApoL2) has a potential apoptotic role being a BH3- protein, localising to mitochondria. This region, known as the ‘BH3-domain’, is essential for the apoptotic function of Bcl-2 autophagy, while the exact role of ApoL2 remains
to be determined, a reduction in the V144D diseased state may cause dysregulation of autophagy [34].

Interestingly, the Chloride intracellular channel protein 1 was identified with a 2.7 fold increased abundance in the HSN-I (SPTLC1 V144D) patient lymphoblasts. We have previously reported this proteins increased expression within the HSN-I (SPTLC1 V144D) patient lymphoblasts [12]. It acts as a chloride-selective ion channel and usually exists in a soluble form in the cytoplasm and nucleoplasm [35], but following stimuli undergoes major structural changes and inserts in lipid membranes, where cell oxidation appears to be an important stimuli determining the transition of Chloride intracellular channel protein 1 between these two forms [36].

It was identified that there were four other proteins with a marked absence or presence in all mitochondrial and ER fractions. These protein species were located at 24 kDa, but each had a different pI (6.6 and 8.3 respectively). Following mass spectral analysis, these proteins identified as Ig Kappa Chain C. This finding correlates with our previous studies in the HSN-I (SPTLC1 V144D) patient lymphoblasts [11,12].

4. Conclusion

This investigation has shown a correlation between previous studies revealing an increase in proteins induced by oxidative stress and mitochondrial electron transport chain proteins. This study also identified changes in calcium channel proteins, cytoskeletal proteins, energy transport proteins. Some of these findings reflect previous studies carried out, providing more evidence for a link of increased misfolded proteins, oxidative stress, and cytoskeleton remodelling and potential changes in Ca²⁺ signalling within the mitochondria. With mounting discoveries into protein alterations in the V144D mutation it may provide a greater in-sight into the molecular mechanisms that are occurring in HSN-I.

5. Materials

All cell culture stock solutions, including RPMI-1640, Foetal Bovine Serum (FBS), Penicillin (100 U/mL), Streptomycin (1 µg/mL), L-glutamine (2 M), HEPES (1 M), and phosphate buffered saline (PBS) were purchased from GIBCO Invitrogen (Australia). Cell culture consumables were purchased from BD Falcon (Greiner, USA).

6. Methods

6.1 EBV transformed lymphoblasts

EBV transformed control and V144D HSN-I patient lymphoblasts were kindly provided by Prof. Garth Nicholson (Molecular Medicine Laboratory, Anzac Research Institute, Sydney) [13].

6.2 Lymphoblast cultures

Lymphoblasts were cultured in RPMI-1640 media (GIBCO), supplemented with FBS (10% v/v), Penicillin (1 U/mL), Streptomycin (1 µg/mL), L-glutamine (2 mM), and HEPES (1 mM) at 37°C in a humidified atmosphere of 5% CO₂, using T75 cm² culture flasks (Greiner, Interpath). Prior to use in biochemical assays, lymphoblasts were collected by centrifugation at 1,500 x g (5 min at RT) and washed in PBS. Cell counts were obtained using the Countess Automated Cell Counter (Invitrogen, Australia).

6.3 Isolation of mitochondrial proteins

Briefly, mitochondria were isolated using a sucrose density gradient [14,15]. Lymphoblasts were first centrifuged at 1,500 x g for 5 min, and the cells were then washed in 10 ml of ice cold 1X PBS prior to suspension in 10 ml ice cold CaSRB Buffer (10 mM NaCl, 1.5 mM CaCl, 10 mM Tris-HCl, pH 7.5) and left on ice for 10 min. Cells were homogenised using a Dounce homogenizer (Kimble-Chase, USA) and 7 ml of 2.5X MS buffer (210 mM Mannitol, 70 mM sucrose, 5 mM EDTA, 5 mM Tris-HCl, pH 7.6) was added to restore isotonicity. Homogenates were centrifuged at 700 x g for 5 min to remove nuclei and unbroken cells. The resulting supernatant was centrifuged at 15,000 x g for 10 min to pellet the crude mitochondria. Sucrose gradients were made in 4 ml high speed centrifuge tubes (Beckman Coulter, USA) by adding 1 ml of 1.7 M sucrose buffer (1.7 M sucrose, 10 mM Tris-base, 0.1 mM EDTA, pH 7.6) overlayed with 1.6 ml of 1.0 M sucrose buffer (1.0 M sucrose, 10 mM Tris-base, 0.1 mM EDTA, pH 7.6). The mitochondrial pellet was resuspended in 1.6 ml of 1x MS buffer and overlayed on top of the sucrose gradient and centrifuged at 40,000 x g for 30 min. The mitochondrial band, in the middle of the gradient, was gently removed using a 20 G needle, transferred to a 1.5 ml tube, and centrifuged at 16,000 x g for 15 min. The resulting pellet was resuspended in 2D solubilisation buffer containing 8 M urea, 2 M thiourea, 4% (w/v) CHAPS and a cocktail of protease inhibitors.

6.4 Isolation of ER proteins

Briefly, [14,15] Lymphoblasts were first centrifuged at 1,500 x g for 5 min, and the cells were then washed in 10 ml of ice cold 1X PBS prior to suspension in 10 ml ice cold CaSRB Buffer (10 mM NaCl, 1.5 mM CaCl, 10 mM Tris-HCl, pH 7.5) and left on ice for 10 min. Cells were homogenised using a Dounce homogenizer (Kimble-Chase, USA) and 7 ml of 2.5 X
total protein extraction buffer (containing 8M urea, previously described [11,16,18,19]; briefly, proteins used for each 2DE analysis. 2DE was carried out as ER protein fractions; a total of 100 µg protein was performed on patient and control mitochondrial and protein concentration estimations (EZQ assay) were 6.6.1

Australia) as previously described [17].

Determination of total cellular protein was performed using the EZQ Protein Estimation Assay (Invitrogen, Australia) as previously described [17].

6.6.1 Two dimensional gel electrophoresis

Protein concentration estimations (EZQ assay) were performed on patient and control mitochondrial and ER protein fractions; a total of 100 µg protein was used for each 2DE analysis. 2DE was carried out as previously described [11,16,18,19]; briefly, proteins were reduced and alkylated in solutions containing total protein extraction buffer (containing 8M urea, 2M thiourea and 4% CHAPS without ampholytes), total extraction buffer with 2% ampholytes, TBP/DTT disulphide reduction buffer (2.3 mM Tributyl phosphine and 45 mM DTT) and alkylation buffer (230 mM acrylamide monomer).

The treated samples were added to 7 cm Non-Linear pH 3-10 IPG strips (Bio-Rad ReadyStrip), and rehydrated for 16 h at RT. Isoelectric focusing (IEF) was then carried out at 20º C using the Protean IEF Cell (Bio-Rad, USA). After IEF, IPG strips were then resolved in the second dimension using a 12.5% T, 2.6% C polyacrylamide gel buffered with 375 mM Tris buffer (pH 8.8), 0.1% (w/v) sodium dodecyl sulphate and polymerised with 0.05% (w/v) ammonium persulphate and 0.05% (v/v) tetramethylethlenediamine (TEMED). A stacking gel containing a 5% T, 2.6% C polyacrylamide buffered with 375 mM Tris buffer (pH 8.8), 0.1% (w/v) SDS and included 0.1% bromophenol blue was added to the resolving gel. The IPG strips were placed onto the stacking gel and overlaid with 0.5% (w/v) low melting agarose dissolved in 375 mM Tris (pH 8.8), with 0.1% (w/v) SDS. Electrophoresis was carried out at 4º C; 150V initially for 10 min then reduced to 90V for 2.5 h. The gels were placed in fixative containing 10% methanol and 7% acetic acid for 1 h. The gels were washed with distilled water for 20 min, 3 times and subsequently stained with colloidal coomassie blue (0.1% (w/v) CCB G-250, 2% (v/v) phosphoric acid, 10% (w/v) ammonium sulphate, 20% (v/v) methanol) for 20 h, with constant shaking at RT [18]; the gels were the de-stained 5 times with 0.5 M NaCl, 15 min each. Imaging of CBB-stained gels on the FLA-9000 imager (FUJIFILM, Tokyo, Japan) was carried out at 685/750 excitation/emission with a photomultiplier tube (PMT) setting of 600 V and pixel resolution set to 100 µm [18]. Analysis of 2D gel images was performed using Delta 2D software (version 4.0.8; DECODON GmbH, Gerifswald, Germany) with automated spot detection (Local Background Region: 96; Average Spot Size: 32 and sensitivity in percentage: 20.0) (Figure 3 and 4).

6.6.2 Mass spectrometry

For analysis a selection criteria was applied. For inclusion, changes in mean normalised spot volume (the abundance of resolved protein species) had to be greater than or equal to a 2.0 fold increase or decrease between control and HSN-I (SPTLC1 V144D) patient lymphoblast, have a p-value <0.05 and be present in all replicate gels [18,19]. The protein species of interest were excised from gels and de-stained overnight. The gel pieces were then reduced and alkylated in 10 mM Dithiothreitol (DTT) and 15 mM Iodoacetic acid (IAA), and subsequently incubated with trypsin solution (10 ng/µL, pH 7.4) for 16 h at 37ºC. LC-MS/MS analysis was carried out on a nanoAcquity UPLC (Waters Corp., Milford, MA, USA) linked to a Xevo QToF mass spectrometer from
Waters (Micromass, UK). The data were acquired using Masslynx software (Version 4.1, Micromass UK). The MS/MS data files were searched against SwissProt databases with semi-trypsin as the enzyme. The following parameters were used in Mascot for identification of the peptides: maximum missed cleavage of 2, positive peptide charge of 2, 3 and 4, peptide mass tolerant of 0.5 Da in MS and MS/MS data base, fixed modification: carboxamidomethyl (C) and variable modifications: oxidation (M).

7. Competing Interests
The authors have no competing interests.

8. Author Contributions
SES carried out all experimentation, data analysis and wrote an initial draft of the manuscript; JRC participated in design of study, provided access to the proteomics facility in which the bulk of the work was carried out, and re-drafted substantial portions of the draft; SJM conceived the study, participated in design of study; re-drafted substantial sections of the drafts. All authors read and approved the final manuscript.

Acknowledgements
We are grateful to Prof Garth Nicholson (Molecular Medicine Laboratory and Northcott Neuroscience Laboratory Anzac Research Institute, Sydney) for providing all EBV transformed lymphoblast lines used in this study. SES was supported by an APA Research Scholarship, and the UWS School of Science and Health Postgraduate research fund. SJM notes the continuing support of an anonymous Private Foundation. JRC acknowledges the support of the UWS School of Medicine.

List of Abbreviations
2DE, two dimensional gel electrophoresis; ApoL2, Apolipoprotein L2.; DRG, dorsal root ganglion; DTT, Dithiothreitol; elf2A, Eukaryotic translation factor 5A-1; ER, endoplasmic reticulum; FBS, Foetal Bovine Serum; HSN, Hereditary sensory neuropathies; HSN-I, Hereditary sensory neuropathy type I; IAA, Idoacetic acid; IEF, Isoelectric focusing; kDa, Kilodaltons; LCBI, long-chain base one; LC/MS, liquid chromatography/ mass spectrometry; PBS, phosphate buffered saline; PMT, photomultiplier tube; PSME1, Proteasome activator complex subunit 1; PSMA3, Proteasome subunit alpha type-3; ROS, reactive oxygen species; S CaMc-1, Calcium binding mitochondrial carrier protein 1; SPT, serine palmitoyltransferase; SPTLC1, serine palmitoyltransferase long chain subunit 1; TEMED, tetramethylethylenediamine; VDAC, Voltage dependent anion-selective channel protein 1.

References
transfected cells and from human cytomegalovirus-infected primary fibroblasts. *Curr Protoc Cell Biol.* 27.


